NCT07230912Not yet recruiting
Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes
Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes, Severity and Response to Therapy
Source: ClinicalTrials.gov · Last updated 17 Nov 2025
Brief summary (registry, in English)
* Assess response to treatment in children with bronchial asthma attending Assiut university children hospital. * Role of comorbidities in controlling symptoms of bronchial asthma. * Evaluate the role of the soluable interleukin 5 receptor, I C-telopeptide of type I collagen (ICTP), miR-223-3p and miR-191-5p in bronchial asthma.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 82 (estimated)
- First submitted
- 2 Oct 2025
- Start date
- 30 Dec 2025
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Assiut University
- Diseases
- Asthma
- NCT number
- NCT07230912
What you commit to
- Study type: Observational
- Planned participants: 82
- From 30 Dec 2025 to the primary completion date, 30 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Chronic respiratory illness other than asthma (e.g., bronchiectasis, CF)
- Known immunodeficiency or systemic illness
Other
- patients with skeletal deformities
- patients suspected inborn errors of metabolism
Who the study is looking for
- Children aged 6-12 years diagnosed asthma, inpatient or attending pediatric outpatient clinic of Assiut university children hospital.
Age in the registry: 6 years to 12 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.